secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2026-08-11T11:15:17+00:00
Accession:  0001193125-26-343428
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica Q2 net loss $7.7M, $49M financing, FDA aligns on AP trial
---------------------------------------------------------------------

- Net loss Q2 2026 $7.7M ($0.45/share) vs $6.0M ($0.40) year ago.
- Cash $18.6M at June 30, 2026; expected to fund operations into H2 2027.
- Private placement up to ~$49M gross (~$15M upfront) to advance pulmonary hypertension program.
- FDA aligned on Phase 2b design for Auxora in acute pancreatitis; primary endpoint new-onset severe respiratory failure.
- Auxora Phase 1b PAH data and CM5480 IND submission both anticipated mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000119312526343428/0001193125-26-343428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000119312526343428/ck0001534133-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-343428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer